Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12436062 | 0.81 | PTGES (0.40) | L3MBTL1KDM4EPOLB | |
| SCHEMBL24423925 | 0.81 | CACNA1H (0.43) | ATRMAPKAPK2L3MBTL1STK17BSTK17A | |
| SCHEMBL21455353 | 0.80 | ATR (0.44) | ATRMAPKAPK2L3MBTL1STK17BSTK17A | |
| SCHEMBL23509054 | 0.80 | ATR (0.50) | ATRMAPKAPK2L3MBTL1LMNANAMPT | |
| SCHEMBL31391134 | 0.79 | KDM4E (0.33) | ATRMAPKAPK2KDM4ELMNAGAA | |
| SCHEMBL13201540 | 0.78 | NPSR1 (0.42) | MAPKAPK2L3MBTL1LMNAPOLB | |
| SCHEMBL12578946 | 0.78 | ATR (0.47) | ATRL3MBTL1KDM4ELMNAGAA | |
| SCHEMBL30890544 | 0.78 | CHRM2 (0.47) | MAPKAPK2L3MBTL1KDM4EKDM4ANAMPT | |
| SCHEMBL1631864 | 0.78 | ADORA2A (0.48) | L3MBTL1KDM4ANAMPT | |
| SCHEMBL18099749 | 0.77 | POLB (0.43) | KDM4ENAMPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600721-B2 | TYK2 inhibitors and uses thereof | SUDO BIOSCIENCES LIMITED (GB) | 2026-04-14 | — | — | US | disclosed |
| US-20240199610-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| EP-4294806-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022175746-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-08-25 | — | — | WO | disclosed |
| EP-3484879-B1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2020-12-30 | — | — | EP | disclosed |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-02-05 | — | — | US | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | ATR 3195/4885MAPKAPK2 867/4885L3MBTL1 4129/4885 |
| US-12600721-B2 | TYK2 inhibitors and uses thereof | TYK2, CSNK2A3, JAK1 | ATR 274/4885MAPKAPK2 198/4885L3MBTL1 2176/4885 |
| US-20240199610-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ATR 338/4885MAPKAPK2 53/4885L3MBTL1 1445/4885 |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | ATR 3195/4885MAPKAPK2 867/4885L3MBTL1 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.